Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 5304

Special Issue Editor

Prof. Dr. Sunga Choi

E-Mail
Guest Editor
Department of Bioinformatics & Biosystems, Korea Polytechnics 398, Sujeong-ro, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
Interests: triple negative breast cancer; acetylation; anti-tumor drug; resistancy; natural compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is still one of the leading causes of death despite remarkable advances in diagnostics and therapy represented by targeted treatments in recent decades. Multi-faceted approaches and better access are further required for complicated tumor patients. One such approach is therapeutic intervention targeting the signaling network formed between the cancer and inflammatory-related immune cells in the tumor microenvironment. A tumor is formed as a result of chronic inflammation that promotes malignant cellular transformation. Tumor cells are influenced by the surrounding tumor microenvironment; several pro-inflammatory mediators and chemokines have been shown to participate in tumorigenesis, even in its pleiotropic roles in biological processes. Therefore, immunological modulation of cytokine-mediated inflammation has been determined in malignant tumors, and it has shown tumor immune evasion.

This Special Issue aims to collect recent topics and aspects of cross-talk between tumor and inflammatory immune cells. In addition, it will discuss the relationship between metastasis and its drug resistance to anti-cancer agents. The knowledge developed may finally lead to breakthroughs in treating chronic and complicated tumor cells. We welcome experts in this field to contribute with original research, mini and full reviews, and perspectives.

Dr. Sunga Choi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • cancer progression and metastasis
  • inflammatory-related immune cells in the tumor microenvironment
  • signal transduction in cancer cells
  • drug resistance
  • potential agents causing epigenetic modification
  • epithelial–mesenchymal transition and agents leading reverse EMT
  • receptor blockers

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2394 KiB  
Article
Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression
by Alena Laschtowitz, Joeri Lambrecht, Tobias Puengel, Frank Tacke and Raphael Mohr
Int. J. Mol. Sci. 2023, 24(6), 5295; https://doi.org/10.3390/ijms24065295 - 10 Mar 2023
Cited by 1 | Viewed by 1550
Abstract
Chemokines or chemotactic cytokines play a pivotal role in the immune pathogenesis of liver cirrhosis and hepatocellular carcinoma (HCC). Nevertheless, comprehensive cytokine profiling data across different etiologies of liver diseases are lacking. Chemokines might serve as diagnostic and prognostic biomarkers. In our study, [...] Read more.
Chemokines or chemotactic cytokines play a pivotal role in the immune pathogenesis of liver cirrhosis and hepatocellular carcinoma (HCC). Nevertheless, comprehensive cytokine profiling data across different etiologies of liver diseases are lacking. Chemokines might serve as diagnostic and prognostic biomarkers. In our study, we analyzed serum concentrations of 12 inflammation-related chemokines in a cohort of patients (n = 222) with cirrhosis of different etiologies and/or HCC. We compared 97 patients with cirrhosis and treatment-naïve HCC to the chemokine profile of 125 patients with cirrhosis but confirmed absence of HCC. Nine out of twelve chemokines were significantly elevated in sera of cirrhotic patients with HCC compared to HCC-free cirrhosis controls (CCL2, CCL11, CCL17, CCL20, CXCL1, CXCL5, CXCL9, CXCL10, CXCL11). Among those, CXCL5, CXCL9, CXCL10, and CXCL11 were significantly elevated in patients with early HCC according to the Barcelona Clinic Liver Cancer (BCLC) stages 0/A compared to cirrhotic controls without HCC. In patients with HCC, CXCL5 serum levels were associated with tumor progression, and levels of CCL20 and CXCL8 with macrovascular invasion. Importantly, our study identified CXCL5, CXCL9, and CXCL10 as universal HCC markers, independent from underlying etiology of cirrhosis. In conclusion, regardless of the underlying liver disease, patients with cirrhosis share an HCC-specific chemokine profile. CXCL5 may serve as a diagnostic biomarker in cirrhotic patients for early HCC detection as well as for tumor progression. Full article
(This article belongs to the Special Issue Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

48 pages, 3346 KiB  
Review
The Killer’s Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer
by Marisabel Mecca, Simona Picerno and Salvatore Cortellino
Int. J. Mol. Sci. 2024, 25(5), 2750; https://doi.org/10.3390/ijms25052750 - 27 Feb 2024
Viewed by 1061
Abstract
Inflammation is a key contributor to both the initiation and progression of tumors, and it can be triggered by genetic instability within tumors, as well as by lifestyle and dietary factors. The inflammatory response plays a critical role in the genetic and epigenetic [...] Read more.
Inflammation is a key contributor to both the initiation and progression of tumors, and it can be triggered by genetic instability within tumors, as well as by lifestyle and dietary factors. The inflammatory response plays a critical role in the genetic and epigenetic reprogramming of tumor cells, as well as in the cells that comprise the tumor microenvironment. Cells in the microenvironment acquire a phenotype that promotes immune evasion, progression, and metastasis. We will review the mechanisms and pathways involved in the interaction between tumors, inflammation, and nutrition, the limitations of current therapies, and discuss potential future therapeutic approaches. Full article
(This article belongs to the Special Issue Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention 2.0)
►▼ Show Figures

Figure 1

16 pages, 1114 KiB  
Review
Biofilm and Cancer: Interactions and Future Directions for Cancer Therapy
by Euna Choi, Ben Murray and Sunga Choi
Int. J. Mol. Sci. 2023, 24(16), 12836; https://doi.org/10.3390/ijms241612836 - 16 Aug 2023
Cited by 3 | Viewed by 2224
Abstract
There is a growing body of evidence supporting the significant role of bacterial biofilms in the pathogenesis of various human diseases, including cancer. Biofilms are polymicrobial communities enclosed within an extracellular matrix composed of polysaccharides, proteins, extracellular DNA, and lipids. This complex matrix [...] Read more.
There is a growing body of evidence supporting the significant role of bacterial biofilms in the pathogenesis of various human diseases, including cancer. Biofilms are polymicrobial communities enclosed within an extracellular matrix composed of polysaccharides, proteins, extracellular DNA, and lipids. This complex matrix provides protection against antibiotics and host immune responses, enabling the microorganisms to establish persistent infections. Moreover, biofilms induce anti-inflammatory responses and metabolic changes in the host, further facilitating their survival. Many of these changes are comparable to those observed in cancer cells. This review will cover recent research on the role of bacterial biofilms in carcinogenesis, especially in colorectal (CRC) and gastric cancers, emphasizing the shared physical and chemical characteristics of biofilms and cancer. This review will also discuss the interactions between bacteria and the tumor microenvironment, which can facilitate oncogene expression and cancer progression. This information will provide insight into developing new therapies to identify and treat biofilm-associated cancers, such as utilizing bacteria as delivery vectors, using bacteria to upregulate immune function, or more selectively targeting biofilms and cancer for their shared traits. Full article
(This article belongs to the Special Issue Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop